PCRX
Pacira BioSciences, Inc. · Healthcare · Drug Manufacturers - Specialty & Generic
Momentum inputs (comparable managers): holder breadth 0.0% · share flow +30.0% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 87 | +2 | 30.81M | $780.79M | +7 | −6 |
| Q1 2026 | 89 | -5 | 30.76M | $694.94M | +2 | −7 |
| Q4 2025 | 94 | -1 | 36.25M | $938.05M | n/a | −1 |
| Q3 2025 | 19 | +1 | 24.74M | $637.46M | +2 | −1 |
| Q2 2025 | 15 | 0 | 22.66M | $541.65M | +1 | −1 |
| Q1 2025 | 12 | -3 | 10.29M | $255.59M | n/a | −3 |
| Q4 2024 | 15 | +1 | 11.71M | $220.69M | +1 | n/a |
| Q3 2024 | 13 | 0 | 9.23M | $138.98M | +1 | −1 |
| Q2 2024 | 13 | n/a | 6.89M | $197.00M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Renaissance Technologies ✦ | 1.98M | -4.2% | $29.78M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 2 | D. E. Shaw & Co. ✦ | 1.96M | +307.3% | $29.45M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 3 | Arrowstreet Capital ✦ | 1.15M | +2058.1% | $17.35M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 4 | Geode Capital Management ✦ (passive) | 1.09M | -0.2% | $16.36M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 5 | Millennium Management ✦ | 606.04K | New | $9.12M | 0.0% | New | 1 | SEC ↗ |
| 6 | AQR Capital Management ✦ | 546.21K | +707.8% | $8.22M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 7 | Marshall Wace ✦ | 524.95K | -46.0% | $7.90M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 8 | Wellington Management ✦ | 454.65K | -6.7% | $6.84M | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 9 | Citadel Advisors ✦ | 446.53K | +48.8% | $6.72M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 10 | Norges Bank ✦ (passive) | 269.30K | +28.2% | $4.05M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 11 | Gotham Asset Management ✦ | 90.91K | +214.3% | $1.37M | 0.0% | ▲ Add | 2 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 69.46K | -8.6% | $1.05M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 13 | T. Rowe Price ✦ | 50.72K | -79.6% | $764,000 | 0.0% | ▼ Trim | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Millennium Management | $9.12M | 0.0% |
Exited
| Baillie Gifford | $23.06M | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 3 holders, 13.02M shares, $12.57M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 6.00K sh · $217,920
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology